Brain mapping instruments market seen reaching $3.33 billion by 2030

The brain mapping instruments market is projected to grow from $2.58 billion in 2026 to $3.33 billion by 2030, driven by rising neurological disorder cases and wider use of advanced imaging tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Brain mapping instruments are central to neurological diagnosis, research and treatment planning. - Demand is rising as hospitals, researchers and care teams use these tools to better understand brain structure, function and disease. - The market outlook points to steady growth in a field tied closely to precision medicine and neurotherapeutics.

What happened: - The brain mapping instruments market is projected to rise from $2.58 billion in 2026 to $3.33 billion by 2030. - The forecast implies a compound annual growth rate of 6.6%. - The Business Research Company published the market study on July 29, 2026. - A free sample of the report is available here. - The full report is available here.

The details: - Brain mapping instruments are specialized tools that visualize, measure and analyze the brain's structure and function. - The tools use multiple technologies to generate images and data on brain activity, connectivity and anatomy. - The market grew from $2.42 billion in 2025 to $2.58 billion in 2026. - Historical growth was supported by stronger diagnosis programs for neurological disorders, wider use of EEG and CT-based brain mapping systems, early adoption of neuroimaging in hospitals and research institutions, more brain activity monitoring in clinical neurology and higher neuroscience research spending. - Forecast growth is linked to broader use of functional brain mapping techniques such as fMRI and PET, more adoption of hybrid and high-resolution imaging tools, rising use of non-invasive mapping in ambulatory care, greater integration of multimodal brain analysis technologies and expanding use in precision medicine and neurotherapeutics. - The report highlights a shift toward non-invasive, patient-friendly procedures that improve imaging accuracy, data quality and diagnostic effectiveness. - In 2025, North America led the market by size. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The biggest demand driver is the rising prevalence of neurological disorders worldwide. - Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis and stroke are increasing pressure on health systems and research budgets. - Aging populations, urbanization, lifestyle changes, better diagnosis and environmental and infectious risks are contributing to that burden. - In March 2023, the Alzheimer’s Association reported about 6.7 million Americans age 65 and older were living with Alzheimer’s dementia, with that number projected to reach 13.8 million by 2060. - The regional split suggests mature healthcare systems are driving current revenue, while faster adoption in Asia-Pacific may shape the next phase of expansion.

What's next: - The market is expected to keep expanding as hybrid imaging, non-invasive tools and multimodal analysis become more common. - Brain mapping use in clinical diagnosis and treatment planning is likely to broaden. - The report’s 2026 additions include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables. - The Business Research Company provided contact details for expert follow-up and sales inquiries.

The bottom line: - Brain mapping instruments are moving from a specialized research category into a broader clinical growth market, with neurological disease burden and advanced imaging adoption pushing demand through 2030.